secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001293971-24-000010
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio restates 2019-2023 financials due to lease accounting errors; going concern doubt reaffirmed
--------------------------------------------------------------------------------

- Restating financials for 2019-2022 annual and interim periods; lease assets/liabilities understated by $100-200M.
- Material weakness in internal controls over financial reporting; CEO and CFO conclude disclosure controls ineffective.
- Full-year 2023 revenue $29.5M (ZYNTEGLO $16.7M, SKYSONA $12.4M); cash position $275M at Dec 31, 2023.
- Entered up to $175M term loan with Hercules Capital; $75M drawn; cash runway expected through Q1 2026.
- 2024 guidance: 85-105 total patient starts; first LYFGENIA revenue expected in Q3 2024; gross-to-net discounts 20-25%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/0001293971-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000010/blue-20240324.htm
  HTML page:      https://secwatch.observer/filing/0001293971-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer